TransCode Therapeutics, Inc. (RNAZ) Ownership
RNAZ ownership summary
as of October 18, 2026- Institutions
- 0.4% of shares outstanding
- Insiders
- 1.78% of shares outstanding
- Shares outstanding
- 16.9M
- Float
- 2.2M shares available to trade
- Short interest
- 0.31% 52K shares short
- Days to cover
- 0.59 short interest down 15.2% vs prior month
- Institutions 0.44%
- Insiders 1.78%
- Other investors 97.78%
RNAZ top institutional holders
13 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Yorkville Advisors Global, LP | 0.12% | 20K | $33,386 | +19,639 (0.0%) | June 30, 2026 |
| 2 | Vanguard Capital Management, LLC | 0.04% | 6,545 | $11,126 | — | June 30, 2026 |
| 3 | Vanguard Fiduciary Trust Co | 0.02% | 2,982 | $5,069 | — | June 30, 2026 |
| 4 | UBS Group AG | 0.02% | 2,888 | $4,910 | −5,407 (−65.2%) | June 30, 2026 |
| 5 | Mercer Global Advisors Inc. | 0.01% | 1,535 | $2,610 | +1,535 (0.0%) | June 30, 2026 |
| 6 | FMR Inc | <0.01% | 706 | $1,200 | +706 (0.0%) | June 30, 2026 |
| 7 | Tower Research Capital LLC | <0.01% | 677 | $1,151 | +449 (+196.9%) | June 30, 2026 |
| 8 | Wells Fargo & Co | <0.01% | 55 | $94 | — | June 30, 2026 |
| 9 | SBI Securities Co Ltd | <0.01% | 12 | $20 | — | June 30, 2026 |
| 10 | Royal Bank of Canada | 0.00% | 8 | $14 | — | March 31, 2026 |
| 11 | Geode Capital Management, LLC | 0.00% | — | — | −12,740 (−100.0%) | June 30, 2026 |
| 12 | Advisor Group Holdings, Inc. | 0.00% | — | — | −3 (−100.0%) | March 31, 2026 |
| 13 | Bank of America Corp | 0.00% | — | — | −8 (−100.0%) | March 31, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 13, 4 holders added 22K shares and 4 cut 18K.
RNAZ top mutual fund and ETF holders
3 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Fidelity Extended Market Index | 0.03% | 5,086 | $8,646 | −27 (−0.5%) | August 31, 2026 |
| 2 | Fidelity Series Total Market Index | 0.01% | 1,180 | $2,006 | — | August 31, 2026 |
| 3 | Fidelity Total Market Index | <0.01% | 510 | $867 | — | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
RNAZ insider transactions
latest 4| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2023-09-28 | Robert Michael Dudley | Buy | $18,849.60 | 2 | $37,699 |
| 2023-09-28 | Thomas A Fitzgerald | Buy | $18,849.60 | 1 | $18,850 |
| 2023-06-20 | Robert Michael Dudley | Buy | $94,248.00 | — | — |
| 2023-06-09 | Robert Michael Dudley | Buy | $102,009.60 | — | — |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
RNAZ shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns RNAZ
Institutional investors own 0.4% of TransCode Therapeutics's shares and insiders 1.78%. The largest holder is Yorkville Advisors Global, LP with 0.12% of the shares (20K), as of June 30, 2026. Among the top 13 institutions, 4 added shares and 4 reduced their stake in the latest filings. Short interest is 0.31% of the float, or 0.59 days of average trading volume. The share count rose 458,400.0% since 2019.
Related: RNAZ analyst forecast, RNAZ key metrics. See the RNAZ stock overview for the latest quote and news.
RNAZ ownership FAQ
Who owns the most TransCode Therapeutics stock?
The largest shareholders of TransCode Therapeutics are Yorkville Advisors Global, LP (0.12%), Vanguard Capital Management, LLC (0.04%), Vanguard Fiduciary Trust Co (0.02%), UBS Group AG (0.02%), Mercer Global Advisors Inc. (0.01%).
What percentage of TransCode Therapeutics is owned by institutions?
Institutions hold 0.4% of TransCode Therapeutics's shares outstanding; insiders hold 1.78%.
Which funds own TransCode Therapeutics?
The largest fund holders of TransCode Therapeutics are Fidelity Extended Market Index (0.03%), Fidelity Series Total Market Index (0.01%), Fidelity Total Market Index (<0.01%).
What is TransCode Therapeutics's short interest?
52K shares of TransCode Therapeutics were sold short, 0.31% of the float; at the average daily volume it would take 0.59 days to cover.
Are insiders buying or selling TransCode Therapeutics?
Of the latest 4 reported insider transactions in TransCode Therapeutics (since June 9, 2023), 4 were purchases and 0 were sales.
How many shares of TransCode Therapeutics are outstanding?
TransCode Therapeutics has 16.9M shares outstanding, of which 2.2M are in the public float.